Abstracts tagged "Comparative effectiveness and harms"

Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: 580 • 2018 ACR/ARHP Annual Meeting
Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
Stanley Cohen¹, Heather J Litman², Connie Chen³, Tatjana Lukic³, Ann Madsen³, Liza Takiya⁴, Kimberly J Dandreo², Taylor Blachley² and Jeffrey Greenberg², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Corrona LLC, Waltham, MA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release…
Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Gyanendra Pokharel¹, Rob Deardon¹, Cheryl Barnabe², Vivian P. Bykerk³, Susan J. Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Janet E. Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹ and Glen Hazlewood¹², ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁶Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada, ¹²Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…
Abstract Number: 2877 • 2018 ACR/ARHP Annual Meeting
The Comparative Effectiveness of First-Line Tumor Necrosis Factor Inhibitor (TNFi) Compared with Non-TNFi Agents in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Gregory St. John², Carol J. Etzel¹, Stefano Fiore³, Taylor Blachley¹, Toshio Kimura², Rajeshwari Punekar³, Kelechi Emeanuru⁴, Susan Boklage² and Joel Kremer^1,5, ¹Corrona LLC, Waltham, MA, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi, Bridgewater, NJ, ⁴Corrona, LLC, Waltham, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: RA patients who are intolerant or have an inadequate response to conventional synthetic DMARDs (csDMARDs) can be treated with a biologic DMARD (bDMARD). Tumor…
Abstract Number: 635 • 2017 ACR/ARHP Annual Meeting
Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials
Dongze Wu, Jiang Yue and Lai-Shan Tam, Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: According to EULAR recommendations, in patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, biologic DMARDs targeting IL-12/23,…
Abstract Number: 1825 • 2017 ACR/ARHP Annual Meeting
Comparative Analysis of Achievement of Individual Important Response Measured By DAS28dcrit in a Randomized Head-to-Head Trial of Tocilizumab Vs. Adalimumab in Active Rheumatoid Arthritis
Michaela Koehm¹, Michael Hofmann², Rasmus Lüthje², Matthew McIntosh³, Varghese Abraham³, Cem Gabay⁴, Arthur Kavanaugh⁵, Harald Burkhardt⁶ and Frank Behrens⁶, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ²Rheumatology, Chugai Pharma Europe Ltd., Frankfurt, Germany, ³Genentech, San Francisco, CA, ⁴SCQM, Geneva, Switzerland, Geneva, Switzerland, ⁵Medicine, University of California, San Diego, La Jolla, CA, ⁶Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany
Background/Purpose: Fluctuations in disease activity due to short-term situational effects and measurement errors are important considerations for evaluation of individual clinically meaningful therapeutic response in…
Abstract Number: 2282 • 2017 ACR/ARHP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Interim Report of Baseline Patient Characteristics and Treatment Choices
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Katherine Murphy⁹ and Yukiko Kimura⁶, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke University Medical Center, Durham, NC, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Parent Partner, San Francisco, CA
Background/Purpose: Despite the many available new and effective treatments for polyarticular JIA (P-JIA), there is significant variation in the timing of when biologic medications are…
Abstract Number: 2290 • 2017 ACR/ARHP Annual Meeting
Comparing Effectiveness of Early Initiation of Biologic Treatment for Newly Diagnosed Juvenile Idiopathic Arthritis Using a Novel Statistics Causal Inference Method Applied to Observational Data
Bin Huang¹, Esi Morgan², Chen Chen², Jinzhong Liu², Michelle Adams², Timothy Beukelman³, Hermine I. Brunner⁴ and Daniel J Lovell⁵, ¹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵PRCSG, Cincinnati, OH
Background/Purpose: We compare the effectiveness of two approaches to treat Juvenile idiopathic arthritis (JIA): early combination of biologic and non-biologic disease modifying anti rheumatic drugs…
Abstract Number: 2785 • 2017 ACR/ARHP Annual Meeting
Serious Infections Associated with Tofacitinib in Rheumatoid Arthritis Patients Previously Treated with Methotrexate
Marina Amaral de Avila Machado¹, Cristiano S. Moura², Steve Ferreira Guerra¹, Jeffrey R. Curtis³, Michal Abrahamowicz⁴, Hassan Behlouli¹ and Sasha Bernatsky⁵, ¹Department of Medicine, McGill University Health Centre, Montreal, QC, Canada, ²1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, McGill University Health Centre, Montreak, QC, Canada, ⁵Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Little is known about the real-world safety of tofacitinib, an oral Janus kinase inhibitor. We compared serious infections associated with tofacitinib, disease-modifying antirheumatic drugs…
Abstract Number: 47 • 2017 Pediatric Rheumatology Symposium
Baseline characteristics of the first 123 patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA comparative effectiveness study
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Brian M. Feldman⁵, Mary Ellen Riordan⁶, Anne C. Dennos⁷, Vincent Del Gaizo⁸, Kate Murphy⁹, Yukiko Kimura⁶ and the CARRA Registry Investigators, ¹Seattle Children's Hospital, Seattle, WA, ²Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Pediatrics, Duke Medical Center, Durham, NC, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶Hackensack University Medical Center, Hackensack, NJ, ⁷Duke Clinical Research Institute, Durham, NC, ⁸Parent Partner, Whitehouse Station, NJ, ⁹Patient Partner, San Francisco, CA
Background/Purpose: Many new effective treatments for polyarticular JIA (p-JIA) are available, but there is significant variation among pediatric rheumatologists in the timing of when biologic…
Abstract Number: 946 • 2016 ACR/ARHP Annual Meeting
Comparative Effectiveness of Second-Line Treatment Strategies for Lyme Arthritis in Children
Daniel B. Horton¹, Alysha J. Taxter², Brandt Groh³, David D. Sherry⁴ and Carlos D. Rosé⁵, ¹Pediatrics, Division of Pediatric Rheumatology, Rutgers Robert Wood Johnson Medical School, Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ²Pediatrics, Brenner Children's Hospital, Wake Forest Baptist Medical Center, Winston-Salem, NC, ³Pediatrics, Penn State Milton S. Hershey Medical Center, Hershey, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Division of Pediatric Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Pediatrics, Division of Rheumatology, Nemours/A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE
Background/Purpose: First-line treatment for Lyme arthritis is fairly standardized, but second-line strategies are more variable. We compared the effectiveness of oral antibiotics, intra-articular glucocorticoid injections (IAGC),…
Abstract Number: 1999 • 2016 ACR/ARHP Annual Meeting
Claims-Based Analysis of Cost-Effectiveness Among Patients with Rheumatoid Arthritis Who Switched from a Tumor Necrosis Factor Inhibitor to Another Targeted Disease-Modifying Antirheumatic Drug
Machaon Bonafede¹, Wenhui Wei², Chieh-I Chen³, Donna McMorrow¹, Stefano Fiore⁴, Jonathan Fay³, Toshio Kimura³ and Jeffrey R. Curtis⁵, ¹Truven Health Analytics, Cambridge, MA, ²Sanofi US, Inc., Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Sanofi Genzyme, Bridgwater, NJ, ⁵Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA) who have an inadequate response to a tumor necrosis factor inhibitor (TNFi) can switch to another targeted disease-modifying antirheumatic…
Abstract Number: 2224 • 2015 ACR/ARHP Annual Meeting
Tailored, Online Education on Comparative Effectiveness Studies in Rheumatoid Arthritis: Success in Improving Knowledge and Clinical Decisions
Nimish Mehta, Emilie McCardell and Kathleen Geissel, Medscape, LLC, New York, NY
Background/Purpose: Analysis of past educational activities on comparative effectiveness studies in RA identified different educational needs for varying segments of rheumatologists – from interpretation of…
Abstract Number: 2745 • 2015 ACR/ARHP Annual Meeting
Real World Evaluation of Patients with Rheumatoid Arthritis Initiating Tofacitinib Vs. Adalimumab and Etanercept
Benjamin Chastek¹, James Harnett², Jeffrey R. Curtis³, Robert Gerber⁴, David Gruben⁴, Rui Song⁵ and Andrew Koenig⁶, ¹Optum Insight, Eden Prairie, MN, ²Pfizer Inc, New York, NY, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, Groton, CT, ⁵Optum Insight, Reston, VA, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: In November 2012, the first oral Janus kinase (JAK) inhibitor tofacitinib was approved in the US for the treatment of RA with or without…
Abstract Number: 3095 • 2015 ACR/ARHP Annual Meeting
Initial Results of a Pilot Juvenile Localized Scleroderma (jLS) Comparative Effectiveness Study
Suzanne C. Li¹, Kathryn S. Torok², Sandy D. Hong³, Polly J. Ferguson⁴, C. Egla Rabinovich⁵, Mara L Becker⁶, Fatma Dedeoglu⁷, Maria F. Ibarra⁸, Robert C. Fuhlbrigge^9,10, Katie G. Stewart¹¹, Marilynn G. Punaro¹¹, Thomas Mason II¹², Elena Pope¹³, Ronald Laxer¹⁴, Gloria C. Higgins^15,16 and Brian Feldman¹⁷, ¹Pediatrics, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ⁴Dept of Pediatrics--Rheum, University of Iowa, Iowa City, IA, ⁵Pediatric Rheumatology, Duke Univ Med Ctr, Durham, NC, ⁶Rheumatology, Children's Mercy Kansas City, Kansas City, MO, ⁷Rheumatology, Boston Children's Hospital, Boston, MA, ⁸Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁹Program in Rheumatology, Division of Immunology, Boston Children’s Hospital, Boston, MA, ¹⁰Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹¹Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Dermatology, Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁵Pediatric Rheumatology OSU, Nationwide Childrens Hosp, Columbus, OH, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hospital, Columbus, OH, ¹⁷Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Juvenile localized scleroderma (jLS) is a chronic inflammatory and fibrosing disease that causes severe morbidity, including growth defects, cosmetic deformities, seizures and arthropathy.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].